First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate

Romney M Humphries; Shangxin Yang; Peera Hemarajata; Kevin W Ward; Janet A Hindler; Shelley A Miller; Aric Gregson

doi:10.1128/AAC.01165-15

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate

Antimicrob Agents Chemother. 2015 Oct;59(10):6605-7. doi: 10.1128/AAC.01165-15. Epub 2015 Jul 20.

Authors

Romney M Humphries¹, Shangxin Yang², Peera Hemarajata², Kevin W Ward², Janet A Hindler¹, Shelley A Miller², Aric Gregson³

Affiliations

¹ Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA rhumphries@mednet.ucla.edu jfhindler@mednet.ucla.edu.
² Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA.
³ Department of Medicine, Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, California, USA.

Abstract

Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient with no prior treatment with ceftazidime-avibactam.

MeSH terms

Azabicyclo Compounds / pharmacology*
Bacterial Proteins / metabolism*
Ceftazidime / pharmacology*
Drug Resistance, Bacterial*
Klebsiella pneumoniae / drug effects
Klebsiella pneumoniae / enzymology*
Microbial Sensitivity Tests
beta-Lactamase Inhibitors / pharmacology*
beta-Lactamases / metabolism*

Substances

Azabicyclo Compounds
Bacterial Proteins
beta-Lactamase Inhibitors
avibactam
Ceftazidime
beta-Lactamases
beta-lactamase KPC-3, Klebsiella pneumoniae